Trial Outcomes & Findings for Pediatric Reporting of Adult-Onset Genomic Results (NCT NCT03832985)

NCT ID: NCT03832985

Last Updated: 2026-04-09

Results Overview

The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest anxiety) - 21 (most severe anxiety).

Recruitment status

COMPLETED

Study phase

EARLY_PHASE1

Target enrollment

162 participants

Primary outcome timeframe

Baseline

Results posted on

2026-04-09

Participant Flow

Results reporting is primarily focused on the parent participants who completed data collection, though we now report adolescents' results for primary outcomes. Analysis sample includes parent participants who completed all data collection. Nearly half of consenting parents could not be reached to complete surveys at T2, T3 or T4.

Parents were assigned to a group once their child(ren) received genetic test results. Group 1 comprised parents whose child (or all tested children) had an adult-onset genetic result. Group 2 comprised parents whose child (or all tested children) had a pediatric-onset genetic result. Group 3 comprised parents who child (or all tested children) tested negative for the familial genetic variant. Groups 4-6 are adolescents who corresponded to the parent groups.

Participant milestones

Participant milestones
Measure
Group 1 (Parents of Child(Ren) With Adult-onset Result)
Parents of child(ren) with adult-onset result
Group 2 (Parents of Child(Ren) With Pediatric-onset Result)
Parents of child(ren) with pediatric-onset result
Group 3 (Parents of Child(Ren) Who Tested Negative for Familial Variant)
Parents of child(ren) negative for familial genetic variant
Group 4 (Adolescent With Adult-onset Result)
Adolescents with an adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
Adolescents with pediatric-onset genetic variant
Group 6 (Adolescents Who Tested Negative for Familial Variant)
Adolescents who tested negative for familial genetic variant
Overall Study
STARTED
21
36
35
15
20
35
Overall Study
COMPLETED
13
18
20
4
13
23
Overall Study
NOT COMPLETED
8
18
15
11
7
12

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Added row for adolescents to separate mean (SD) ages for parents and adolescents

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Group 2 (Parents of Children With Pediatric-onset Result)
n=36 Participants
Parents of child(ren) with pediatric-onset result
Group 3 (Parents of Child(Ren) Who Tested Negative for Familial Variant)
n=35 Participants
Parents of child(ren) negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=15 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=20 Participants
Adolescents with pediatric-onset genetic variant
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=35 Participants
Adolescents who tested negative for familial genetic variant
Total
n=162 Participants
Total of all reporting groups
Group 1 (Parents of Child(Ren) With Adult-onset Result)
n=21 Participants
Parents of child(ren) with adult-onset result
Age, Continuous
Parents
38.1 year-old
STANDARD_DEVIATION 8.2 • n=36 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
40 year-old
STANDARD_DEVIATION 9.6 • n=35 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
39.6 year-old
STANDARD_DEVIATION 8.6 • n=92 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
39.5 year-old
STANDARD_DEVIATION 7.6 • n=21 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
Age, Continuous
Adolescents
14.42 year-old
STANDARD_DEVIATION 2.11 • n=15 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
13.85 year-old
STANDARD_DEVIATION 2.56 • n=20 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
14.39 year-old
STANDARD_DEVIATION 2.03 • n=35 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
14.24 year-old
STANDARD_DEVIATION 2.19 • n=70 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
Sex: Female, Male
Female
30 Participants
n=36 Participants
29 Participants
n=35 Participants
9 Participants
n=15 Participants
12 Participants
n=20 Participants
12 Participants
n=35 Participants
110 Participants
n=162 Participants
18 Participants
n=21 Participants
Sex: Female, Male
Male
6 Participants
n=36 Participants
6 Participants
n=35 Participants
6 Participants
n=15 Participants
8 Participants
n=20 Participants
23 Participants
n=35 Participants
52 Participants
n=162 Participants
3 Participants
n=21 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=36 Participants
0 Participants
n=35 Participants
0 Participants
n=15 Participants
0 Participants
n=20 Participants
0 Participants
n=35 Participants
0 Participants
n=162 Participants
0 Participants
n=21 Participants
Race (NIH/OMB)
Asian
0 Participants
n=36 Participants
0 Participants
n=35 Participants
0 Participants
n=15 Participants
0 Participants
n=20 Participants
0 Participants
n=35 Participants
0 Participants
n=162 Participants
0 Participants
n=21 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=36 Participants
0 Participants
n=35 Participants
0 Participants
n=15 Participants
0 Participants
n=20 Participants
0 Participants
n=35 Participants
0 Participants
n=162 Participants
0 Participants
n=21 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=36 Participants
0 Participants
n=35 Participants
0 Participants
n=15 Participants
1 Participants
n=20 Participants
1 Participants
n=35 Participants
4 Participants
n=162 Participants
1 Participants
n=21 Participants
Race (NIH/OMB)
White
32 Participants
n=36 Participants
32 Participants
n=35 Participants
15 Participants
n=15 Participants
16 Participants
n=20 Participants
26 Participants
n=35 Participants
141 Participants
n=162 Participants
20 Participants
n=21 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=36 Participants
0 Participants
n=35 Participants
0 Participants
n=15 Participants
0 Participants
n=20 Participants
0 Participants
n=35 Participants
0 Participants
n=162 Participants
0 Participants
n=21 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants
n=36 Participants
3 Participants
n=35 Participants
0 Participants
n=15 Participants
3 Participants
n=20 Participants
8 Participants
n=35 Participants
17 Participants
n=162 Participants
0 Participants
n=21 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=36 Participants
1 Participants
n=35 Participants
2 Participants
n=15 Participants
1 Participants
n=20 Participants
2 Participants
n=35 Participants
9 Participants
n=162 Participants
1 Participants
n=21 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
33 Participants
n=36 Participants
34 Participants
n=35 Participants
13 Participants
n=15 Participants
16 Participants
n=20 Participants
25 Participants
n=35 Participants
140 Participants
n=162 Participants
19 Participants
n=21 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=36 Participants
0 Participants
n=35 Participants
0 Participants
n=15 Participants
3 Participants
n=20 Participants
8 Participants
n=35 Participants
13 Participants
n=162 Participants
1 Participants
n=21 Participants

PRIMARY outcome

Timeframe: Baseline

Population: Participants who have completed the survey at each follow-up time.

The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest anxiety) - 21 (most severe anxiety).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=35 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=21 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=36 Participants
Adolescents with pediatric-onset genetic variant
The Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale
8.96 units on scale
Standard Deviation 3.10
10.32 units on scale
Standard Deviation 3.68
8.26 units on scale
Standard Deviation 3.33

PRIMARY outcome

Timeframe: Baseline

Population: Participants who have completed the survey at each follow-up time.

The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest) - 21 (most severe).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=35 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=21 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=36 Participants
Adolescents with pediatric-onset genetic variant
The Hospital Anxiety and Depression Scale (HADS) - Depression Subscale
6.33 units on scale
Standard Deviation 2.4
6.79 units on scale
Standard Deviation 2.4
6.61 units on scale
Standard Deviation 2.65

PRIMARY outcome

Timeframe: Baseline

Population: Participants who have completed the survey at each follow-up time.

The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=16 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=25 Participants
Adolescents with pediatric-onset genetic variant
The General Functioning 12-item Subscale (GF12) of The McMaster Family Assessment Device (FAD)
1.7 units of scale
Standard Deviation 0.6
1.7 units of scale
Standard Deviation 0.4
1.5 units of scale
Standard Deviation 0.5

PRIMARY outcome

Timeframe: Baseline

Population: Collapse score 4-5 to 'Fair to Poor'

Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=35 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=21 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=36 Participants
Adolescents with pediatric-onset genetic variant
Health-Related Quality of Life (HRQOL)
6 Participants
3 Participants
8 Participants

PRIMARY outcome

Timeframe: 6+ months post-disclosure to pediatric proband

Population: Analysis only conducted for participants with a pathogenic/likely pathogenic variant in gene of interest (children who tested negative for a relevant genetic variant were not evaluated for initiation of risk reduction procedures). Children of all ages were included in the analysis.

Initiation of risk reduction behavior (yes/no) among children with familial gene variant. Not that this is among children of all ages (not just adolescents). Counts are of participants who initiated a risk reduction behavior. Data were collected via chart review for pre-selected risk reduction procedures specific to each genetic condition. Time in months from results disclosure date to date of risk reduction behavior was tracked.

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=34 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=31 Participants
Adolescents with pediatric-onset genetic variant
Initiation of Risk Reduction Behavior
0 Participants
13 Participants

PRIMARY outcome

Timeframe: 1-month post-disclosure

The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases.Total range is 0 (lowest anxiety) - 21 (most severe anxiety).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=11 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=19 Participants
Adolescents with pediatric-onset genetic variant
The Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale
6.1 units of scale
Standard Deviation 3.91
10.29 units of scale
Standard Deviation 3.43
5.17 units of scale
Standard Deviation 3.92

PRIMARY outcome

Timeframe: 6-month post-disclosure

The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest anxiety) - 21 (most severe anxiety).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=28 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=12 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=21 Participants
Adolescents with pediatric-onset genetic variant
The Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale
5.98 units of scale
Standard Deviation 3.66
10.74 units of scale
Standard Deviation 4.29
5.6 units of scale
Standard Deviation 4.11

PRIMARY outcome

Timeframe: 12-month post-disclosure

The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest anxiety) - 21 (most severe anxiety).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=23 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=10 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=16 Participants
Adolescents with pediatric-onset genetic variant
The Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale
5.5 units of scale
Standard Deviation 3.29
8.9 units of scale
Standard Deviation 4.61
6.12 units of scale
Standard Deviation 4.05

PRIMARY outcome

Timeframe: 1-month post-disclosure

Population: Participants who have completed the survey at each follow-up time.

The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest) - 21 (most severe).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=11 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=19 Participants
Adolescents with pediatric-onset genetic variant
The Hospital Anxiety and Depression Scale (HADS) - Depression Subscale
3.5 units of scale
Standard Deviation 3.12
5.64 units of scale
Standard Deviation 4.67
2.26 units of scale
Standard Deviation 2.54

PRIMARY outcome

Timeframe: 6-month post-disclosure

Population: Participants who have completed the survey at each follow-up time.

The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest) - 21 (most severe).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=28 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=12 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=21 Participants
Adolescents with pediatric-onset genetic variant
The Hospital Anxiety and Depression Scale (HADS) - Depression Subscale
3.33 units of scale
Standard Deviation 3.09
5.0 units of scale
Standard Deviation 3.88
3.42 units of scale
Standard Deviation 3.16

PRIMARY outcome

Timeframe: 12-month post

Population: Participants who have completed the survey at each follow-up time.

The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest) - 21 (most severe).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=23 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=10 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=16 Participants
Adolescents with pediatric-onset genetic variant
The Hospital Anxiety and Depression Scale (HADS) - Depression Subscale
2.39 units of scale
Standard Deviation 2.39
4.4 units of scale
Standard Deviation 3.66
3.31 units of scale
Standard Deviation 3.66

PRIMARY outcome

Timeframe: 1-month post

Population: Participants who have completed the survey at each follow-up time.

The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=21 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=7 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=15 Participants
Adolescents with pediatric-onset genetic variant
The General Functioning 12-item Subscale (GF12) of The McMaster Family Assessment Device (FAD)
1.7 units of scale
Standard Deviation 0.4
1.9 units of scale
Standard Deviation 0.4
1.3 units of scale
Standard Deviation 0.4

PRIMARY outcome

Timeframe: 6-month post

Population: Participants who have completed the survey at each follow-up time.

The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=23 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=8 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=15 Participants
Adolescents with pediatric-onset genetic variant
The General Functioning 12-item Subscale (GF12) of The McMaster Family Assessment Device (FAD)
1.7 units of scale
Standard Deviation 0.5
1.8 units of scale
Standard Deviation 0.5
1.5 units of scale
Standard Deviation 0.4

PRIMARY outcome

Timeframe: 12-month post

Population: Participants who have completed the survey at each follow-up time.

The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=24 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=11 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=17 Participants
Adolescents with pediatric-onset genetic variant
The General Functioning 12-item Subscale (GF12) of The McMaster Family Assessment Device (FAD)
1.6 units of scale
Standard Deviation 0.5
1.5 units of scale
Standard Deviation 0.4
1.4 units of scale
Standard Deviation 0.4

PRIMARY outcome

Timeframe: 1-month post

Population: Collapse score 4-5 to report 'Fair to Poor'

Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=11 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=19 Participants
Adolescents with pediatric-onset genetic variant
Health-Related Quality of Life (HRQOL)
4 Participants
1 Participants
4 Participants

PRIMARY outcome

Timeframe: 6-month post

Population: Collapse score 4-5 to 'Fair to Poor'

Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=27 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=12 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=21 Participants
Adolescents with pediatric-onset genetic variant
Health-Related Quality of Life (HRQOL)
2 Participants
1 Participants
4 Participants

PRIMARY outcome

Timeframe: 12-month post

Population: Collapse score 4-5 to 'Fair to Poor'

Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=28 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=14 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=21 Participants
Adolescents with pediatric-onset genetic variant
Health-Related Quality of Life (HRQOL)
4 Participants
3 Participants
4 Participants

PRIMARY outcome

Timeframe: baseline

Anxiety subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher anxiety).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=25 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=9 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=11 Participants
Adolescents with pediatric-onset genetic variant
Revised Children's Anxiety and Depression Scale - Anxiety Subscale
44.94 T-score
Standard Deviation 12.17
57.23 T-score
Standard Deviation 17.08
40.78 T-score
Standard Deviation 9.51

PRIMARY outcome

Timeframe: 1-month (T2)

Anxiety subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher anxiety).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=17 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=3 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=8 Participants
Adolescents with pediatric-onset genetic variant
Revised Children's Anxiety and Depression Scale - Anxiety Subscale
39.45 T-score
Standard Deviation 10.25
45.83 T-score
Standard Deviation 7.08
45.12 T-score
Standard Deviation 21.28

PRIMARY outcome

Timeframe: 6-month (T3)

Anxiety subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher anxiety).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=14 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=2 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=7 Participants
Adolescents with pediatric-onset genetic variant
Revised Children's Anxiety and Depression Scale - Anxiety Subscale
44.08 T-score
Standard Deviation 13.55
41.44 T-score
Standard Deviation 13.06
37.90 T-score
Standard Deviation 7.11

PRIMARY outcome

Timeframe: 12-month (T4)

Anxiety subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher anxiety).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=14 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=1 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=8 Participants
Adolescents with pediatric-onset genetic variant
Revised Children's Anxiety and Depression Scale - Anxiety Subscale
35.86 T-score
Standard Deviation 10.28
56.85 T-score
Standard Deviation NA
SD not applicable for single participant
44.24 T-score
Standard Deviation 11.20

PRIMARY outcome

Timeframe: Baseline

Depression subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher depression).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=25 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=9 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=11 Participants
Adolescents with pediatric-onset genetic variant
Revised Children's Anxiety and Depression Scale - Depression Subscale
47.46 T-score
Standard Deviation 15.69
59.25 T-score
Standard Deviation 14.03
42.29 T-score
Standard Deviation 11.61

PRIMARY outcome

Timeframe: 1-month (T2)

Depression subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher depression).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=17 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=3 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=8 Participants
Adolescents with pediatric-onset genetic variant
Revised Children's Anxiety and Depression Scale - Depression Subscale
41.04 T-score
Standard Deviation 13.63
48.08 T-score
Standard Deviation 11.85
45.68 T-score
Standard Deviation 17.80

PRIMARY outcome

Timeframe: 6-month (T3)

Depression subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher depression).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=14 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=2 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=7 Participants
Adolescents with pediatric-onset genetic variant
Revised Children's Anxiety and Depression Scale - Depression Subscale
47.02 T-score
Standard Deviation 17.86
51.00 T-score
Standard Deviation 26.79
38.98 T-score
Standard Deviation 7.47

PRIMARY outcome

Timeframe: 12-month (T4)

Depression subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher depression).

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=14 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=1 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=8 Participants
Adolescents with pediatric-onset genetic variant
Revised Children's Anxiety and Depression Scale - Depression Subscale
36.75 T-score
Standard Deviation 9.01
70.55 T-score
Standard Deviation NA
SD not applicable for single participant
44.36 T-score
Standard Deviation 10.87

PRIMARY outcome

Timeframe: baseline

The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=35 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=15 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=20 Participants
Adolescents with pediatric-onset genetic variant
General Functioning 12-item Subscale (GF12) of the McMaster Family Assessment Device (FAD)
1.88 units of scale
Standard Deviation 0.60
1.90 units of scale
Standard Deviation 0.58
1.78 units of scale
Standard Deviation 0.52

PRIMARY outcome

Timeframe: 1-month (T2)

The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=6 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=15 Participants
Adolescents with pediatric-onset genetic variant
General Functioning 12-item Subscale (GF12) of the McMaster Family Assessment Device (FAD)
1.80 units of scale
Standard Deviation 0.66
2.06 units of scale
Standard Deviation 0.46
1.56 units of scale
Standard Deviation 0.45

PRIMARY outcome

Timeframe: 6-month (T2)

The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=25 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=5 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=12 Participants
Adolescents with pediatric-onset genetic variant
General Functioning 12-item Subscale (GF12) of the McMaster Family Assessment Device (FAD)
1.84 units of scale
Standard Deviation 0.61
1.92 units of scale
Standard Deviation 0.38
1.60 units of scale
Standard Deviation 0.44

PRIMARY outcome

Timeframe: 12-month (T2)

The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=23 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=4 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=13 Participants
Adolescents with pediatric-onset genetic variant
General Functioning 12-item Subscale (GF12) of the McMaster Family Assessment Device (FAD)
1.82 units of scale
Standard Deviation 0.72
1.71 units of scale
Standard Deviation 0.73
1.70 units of scale
Standard Deviation 0.47

PRIMARY outcome

Timeframe: Baseline

Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=35 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=15 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=20 Participants
Adolescents with pediatric-onset genetic variant
Health-Related Quality of Life (HRQOL)
0 Participants
1 Participants
1 Participants

PRIMARY outcome

Timeframe: 1-month (T2)

Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=28 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=6 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=15 Participants
Adolescents with pediatric-onset genetic variant
Health-Related Quality of Life (HRQOL)
1 Participants
1 Participants
1 Participants

PRIMARY outcome

Timeframe: 6-month (T3)

Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=24 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=5 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=12 Participants
Adolescents with pediatric-onset genetic variant
Health-Related Quality of Life (HRQOL)
2 Participants
0 Participants
0 Participants

PRIMARY outcome

Timeframe: 12-month (T3)

Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=23 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=4 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=13 Participants
Adolescents with pediatric-onset genetic variant
Health-Related Quality of Life (HRQOL)
1 Participants
0 Participants
0 Participants

SECONDARY outcome

Timeframe: 1- month post-disclosure

Population: Participants who have completed the survey at each follow-up time.

The Decision Regret Scale is made up of 5 items that address the notion of regret in a variety of ways. Scoring on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items. The total score is taken from the mean of the 5 items, and then converted to a 0-100 scale by subtracting 1 from each item then multiply by 25. A score of 0 means no regret; a score of 100 means high regret.

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=11 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=19 Participants
Adolescents with pediatric-onset genetic variant
Decision Regret Scale
8.0 units of scale
Standard Deviation 14.8
15.9 units of scale
Standard Deviation 13.9
7.4 units of scale
Standard Deviation 12.2

SECONDARY outcome

Timeframe: 12- month post-disclosure

Population: Participants who have completed the survey at each follow-up time.

The Decision Regret Scale is made up of 5 items that address the notion of regret in a variety of ways. Scoring on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items. The total score is taken from the mean of the 5 items, and then converted to a 0-100 scale by subtracting 1 from each item then multiply by 25. A score of 0 means no regret; a score of 100 means high regret.

Outcome measures

Outcome measures
Measure
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
Group 4 (Adolescents With Adult-onset Result)
n=11 Participants
Adolescents with adult-onset genetic variant
Group 5 (Adolescents With Pediatric-onset Result)
n=19 Participants
Adolescents with pediatric-onset genetic variant
Decision Regret Scale
5.9 units of scale
Standard Deviation 13.9
7.7 units of scale
Standard Deviation 10.8
8.1 units of scale
Standard Deviation 11.6

Adverse Events

Group 1 (Parents of Child(Ren) With Adult-onset Result)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 2 (Parents of Child(Ren) With Pediatric-onset Result)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 3 (Parents of Child(Ren) Who Tested Negative for Familial Variant)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 4 (Adolescents With Adult-onset Result)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 5 (Adolescents With Pediatric-onset Result)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 6 (Adolescents Who Tested Negative for Familial Variant)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Adam Buchanan

Geisinger

Phone: 570-214-4747

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place